A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

NCT07268053 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma (GBM)
Brain Metastasases

Interventions

DRUG: Risvutatug rezetecan

Sponsor

Nader Sanai

Collaborators

[object Object]